Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

ObservationalRevista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru· 2026

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Paulina Núñez, Rodrigo Quera, Karin Herrera … Romina Fernández

Read paper

Colon & Rectal SurgeryObservationalTreatmentQ4IF 0.3

75% of ulcerative colitis patients on golimumab maintained clinical remission at 24 months.

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Paulina Núñez … Romina Fernández

Revista de gastroenterologia del Peru · 2026 · Q4 in Gastroenterology

Background

Evidence on golimumab for ulcerative colitis (ulcerative colitis) is scarce in Latin America.

Purpose

We aimed to assess the real-world effectiveness and safety of golimumab in a multicenter Chilean cohort.

Methods

We conducted a retrospective, observational study including adult patients with moderate-to-severe ulcerative colitis treated with golimumab under the Chilean government coverage program (July 2019-August 2023).

n = 43 patients

Results

75%

most patients stayed in remission two years later

n = 43 patients

More results

Most were anti-TNF naïve (94%).

At week 16.81% achieved symptomatic remission, 77% biomarker remission, 35% endoscopic remission, and 38% histological remission.

At week 52, 43 patients remained on treatment; of these, 93% achieved symptomatic remission, 98% biomarker remission, 63% endoscopic remission, and 42% histological remission.

More results

Dose optimization was required in 62% of patients, and early optimization was associated with higher remission stability.

“

Conclusion · 1 of 2

In this first Chilean and Latin American multicenter real-world study, golimumab proved effective and safe for moderate ulcerative colitis, achieving high rates of clinical and biomarker remission, particularly with early dose optimization.

Conclusion · 2 of 2

Despite newer biologics and small molecules, golimumab remains a valid therapeutic option in regions with limited access.

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Related papers